Regeneron (REGN) has at least two promising weight-loss candidates in its pipeline. Olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones; in a Phase 3 study in China it led to mean weight loss of up to 19% over 48 weeks, with lower gastrointestinal adverse event rates than some competing drugs, though late-stage U.S. trials are still needed. Trevogrumab is not a weight-loss drug but is designed to be used alongside anti-obesity medicines to help preserve lean mass; in a Phase 2 study with Novo's semaglutide, lean mass preservation reached up to 42.5% versus 7.3% with semaglutide plus placebo. Dupixent, an eczema medicine co-marketed with Sanofi, remains the main growth driver: Regeneron's second-quarter revenue rose 17% year over year to $4.3 billion, and Dupixent's global sales increased 38% to $6 billion. U.S. combined revenue from Eylea and Eylea HD fell 12% to $1 billion amid biosimilar competition, while HD Eylea sales reached $596 million, up 52%.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
REGNpharmaceuticalsweight-loss drugs
Open a keyword to see other news on the same topic.
Related news
- Can Eli Lilly’s (LLY) Growth Machine Keep Delivering?
Eli Lilly (LLY) returned 36.37% over the six months to October 15, compared with 21.5% for the Insider Monkey Billionaire Index and 15.74% for the State Street SPDR S&P 500 ETF Trust. Mounjaro and Zepbound still drive most growth, while Lilly is expanding with the oral obesity drug Foundayo, international markets and treatments beyond obesity, and is investing an additional $4.5 billion in its Indiana facilities. In the second quarter of 2026, revenue rose 48% on a 60% increase in volume, but realized prices fell 13%, partly due to lower international prices, while immunology, oncology and neuroscience products grew 121% combined. LLY trades at 38.64x trailing and 24.39x forward earnings, with forecasts pointing to earnings roughly doubling from last year to next year. The article also flags risks including pricing pressure, heavy spending on production, research and acquisitions, and significant acquired R&D charges in the second quarter.
- This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock
Eli Lilly tested tirzepatide (the active ingredient in Zepbound) combined with eloralintide, an experimental drug targeting the amylin hormone rather than GLP-1. After 48 weeks, the combination produced weight loss of up to 23.3%, versus 14.8% with tirzepatide alone and 12.3% with eloralintide alone. However, discontinuation rates due to side effects reached as high as 27%, though Lilly’s Ken Custer noted that high discontinuation was also seen with tirzepatide in a mid-stage trial and that dosing can matter. The author views the results as a net positive but flags a steep valuation, with a market cap above $1 trillion and the stock trading near 40 times trailing earnings after rising around 10% this year.
- Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A mouse study funded by the NIH found that semaglutide, made by Novo Nordisk and sold as Ozempic and Wegovy, extended the lifespan of older, healthy mice by tempering aging effects, with treated mice showing better muscle and cognitive function. The author assumes that tirzepatide, Eli Lilly's main GLP-1 drug, could show similar effects, though results in humans remain a long way off. Gallup data cited in the article show that US adult use of GLP-1 weight-loss injectables has nearly quadrupled since 2024, reaching 11% this year from 3% two years ago. J.P. Morgan expects about 25 million Americans to be on GLP-1 treatment by 2030, and Morgan Stanley forecasts the market will more than double from 2025 to 2035, to $190 billion.
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's Foundayo, an oral GLP-1 weight-loss medicine approved in the U.S. in April, is drawing new patients, with 80% of its prescriptions earlier this year going to people who had never taken a GLP-1 medicine before. The company's Onswik, a once-weekly basal insulin for diabetes approved in September, could strengthen its diabetes portfolio, though Novo Nordisk's Awiqli was approved first in March. The investigational retatrutide showed average weight loss of up to 28.3% over 80 weeks in one Phase 3 study, and Eli Lilly plans to submit it for regulatory approval in the first quarter of 2027. The article argues these drugs could power Eli Lilly's next phase of growth beyond Zepbound.
- HSE advised to consider public funding for weight - loss jab - but is warned of substantial cost
The National Centre for Pharmacoeconomics (NCPE) has recommended that the HSE consider public funding for semaglutide (Wegovy) for weight loss, finding it cost-effective despite its high price. Funding for up to one million people would cost €4.4 billion over five years, while limiting eligibility to a BMI over 40 with a weight-related condition would cost €265 million over the same period. The NCPE found Wegovy more cost-effective than the rival GLP-1 drug Mounjaro, but warned the budget impact would be “substantial.” The HSE called the recommendation “nuanced,” said its corporate pharmaceutical unit will negotiate prices with manufacturers, and that the budget impact will be discussed in the coming months.
- Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
Related markets
Latest news
- Winning over Vingroup and Sun Group with concrete and special materials: Vietnamese company's profit up 136%, chairman speaks out
Song Da Cao Cuong (SCL) reported Q3/2026 profit of VND 38 billion, up 136%, on net revenue of over VND 263 billion (up nearly 98%), while gross profit margin rose from about 36% to 41%. For the first nine months, revenue reached nearly VND 666 billion (up 81%) and after-tax profit nearly VND 94 billion, already exceeding more than 110% of its full-year profit target. Chairman Kieu Van Mat attributed the results to technology upgrades, production line optimization and capacity expansion, with several new plants expected to start operations by November 2026. The company said it spent more than two years testing its products before Vingroup accepted them; Vingroup's share of its business has fallen to about 25% as customers expanded to around 10 major groups and exports began to Laos, Cambodia and the Philippines. Over the past two years, the company has invested about VND 1,000 billion in factories and technology.
- Coteccons Chairman Bolat Duisenov reveals new direction: expanding home construction for individual customers
At the annual general meeting on October 20, Coteccons (HoSE: CTD) set fiscal 2027 targets of VND 42,000 billion in revenue and VND 1,050 billion in after-tax profit, and said it is considering expanding into residential construction for individual customers (B2C). In fiscal 2026, net revenue reached VND 34,340 billion (up 38%, 115% of plan) and after-tax profit VND 788 billion (up 73%); new contract wins totaled VND 60,307 billion and backlog was about VND 70,000 billion. In the first quarter of the new fiscal year, the company booked revenue of VND 11,270 billion and profit of VND 306 billion, but new contract value of VND 14,519 billion was lower than a year earlier; the company said it is tightening criteria for selecting clients and projects. Coteccons is also working with Microsoft, is expected to become a strategic partner of Workday, and targets raising its ROE from 10% to 15-18% by 2030.
- UPS Yields 6.7% After Firing Amazon. Here's Whether the Dividend Survives 2027.
UPS shares yield 6.7% as of October 16. The company has moved away from high-volume, low-margin Amazon deliveries and froze its dividend earlier this year, ending a 16-year streak of increases. The article says the payout will likely remain frozen through 2026 and 2027, citing competition from 10- and 30-year Treasury yields above 5% and other industrial dividend payers, but calls the dividend's safety questionable: UPS generated $5.47 billion in free cash flow in 2025, with $5.4 billion going to dividends, and free cash flow is projected to fall to $5.05 billion in 2026 and $5.01 billion in 2027, with the dividend absorbing about 98% of 2026 free cash flow. Rising competition and high fuel prices add pressure, and the article suggests investors may find more safety in the industrial sector.
- Asian shares mostly decline after AI stocks lead a rebound on Wall Street
Asian shares mostly fell in cautious trading on Tuesday after AI-related stocks rebounded on Wall Street, while other sectors stayed shaky and oil prices stayed high. Japan's Nikkei 225 slipped 0.6% to 64,512.35 in early trading, South Korea's Kospi dropped 2.8%, and Australia's S&P/ASX 200 lost 0.8%. On Wall Street, the S&P 500 rose 0.4% and the Nasdaq gained 1.1%, helped by Nvidia's 1.4% gain, while most stocks outside AI and tech fell and the Dow slipped 0.1%. The 10-year Treasury yield climbed to 5.14%, and U.S. crude rose to $103.50 a barrel and Brent to $109.47, as uncertainty about when the energy industry will return to normal after the war with Iran means oil is unlikely to ease soon.
- Asian shares mostly decline after AI stocks lead a rebound on Wall Street
Asian shares mostly fell in cautious trading Tuesday after AI-related stocks rebounded on Wall Street, while other sectors stayed shaky and oil prices remained high. Japan's Nikkei 225 slipped 0.6% to 64,512.35, Australia's S&P/ASX 200 lost 0.8% to 8,772.10, and South Korea's Kospi dropped 2.8% to 5,605.31. On Wall Street, the S&P 500 rose 0.4% and the Nasdaq rallied 1.1%, helped by Nvidia, while the Dow fell 0.1%. The 10-year Treasury yield climbed to 5.14%, and U.S. crude rose 0.15% to $103.50 a barrel as uncertainty over the war with Iran kept oil prices elevated.
- What Could X-Energy (XE) Gain From Its 960MW Indiana Nuclear Project?
X-Energy (NasdaqGS:XE), American Electric Power and Amazon agreed to assess a 960 MW advanced nuclear project in Indiana using Xe-100 reactors, on a former coal plant site. Under the joint development agreement, Amazon would provide development funding and commit to a long-term power purchase. The article says the deal offers commercial validation for X-Energy's reactor platform rather than immediate financial relief, as the company, with a $4.3b market cap, reported $150.28 million in revenue, a $448.87 million loss, and a 20.2x price-to-sales ratio. The next key milestone is whether the study reaches a final investment decision for the Sullivan County site.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.